Loading...

PE Streptavidin

Pricing & Availability
Regulatory Status
RUO
Other Names
Streptavidin-Phycoerythrin, SAv-PE
Ave. Rating
Submit a Review
Product Citations
publications
SAV_PE_082808.jpg
C57BL/6 splenocytes stained with 145-2C11 biotin, followed by SAV-PE
  • SAV_PE_082808.jpg
    C57BL/6 splenocytes stained with 145-2C11 biotin, followed by SAV-PE
See PE spectral data
Cat # Size Price Save
405203 100 µg ¥12,320
405204 500 µg ¥42,900
Description

Streptavidin binds to biotin with high affinity. Streptavidin-Phycoerythrin (PE) is useful for detecting biotinylated antibodies. The excitation of PE by 488 nm laser light induces a light emission maximum of 575 nm.

Product Details
Technical data sheet

Product Details

Verified Reactivity
Human, Mouse, Rat, All Species
Formulation
Phosphate-buffered solution, pH 7.2, containing 0.09% sodium azide.
Preparation
Streptavidin is conjugated with PE under optimal conditions.
Concentration
0.2 mg/ml (concentration relates to the Streptavidin only component of the conjugate)
Storage & Handling
The streptavidin-PE solution should be stored undiluted between 2°C and 8°C, and protected from exposure to light. Do not freeze.
Application

FC - Quality tested

ICFC - Verified
Recommended Usage

This streptavidin product is quality control tested by immunofluorescent staining with flow cytometric analysis. The concentration provided is based upon molecular mass of streptavidin independent of any additional molecular mass that might be added by the PE conjugation. For flow cytometric staining, the suggested use of this reagent is ≤0.06 µg per million cells in 100 µl volume. It is recommended that the reagent be titrated for optimal performance for each application.

Excitation Laser
Blue Laser (488 nm)
Green Laser (532 nm)/Yellow-Green Laser (561 nm)
Application Notes

Streptavidin-Phycoerythrin (PE) is useful as a second step reagent for indirect immunofluorescent staining, when used in conjunction with biotinylated primary antibodies. The average molecular weight of Streptavidin-PE is 360 kD and Streptavidin alone is 52 kD.

Application References

(PubMed link indicates BioLegend citation)
  1. Chappaz S, et al. 2007. Blood doi:10.1182/blood-2007-02-074245.
  2. Nishimoto KP,et al. 2008. J. Immunol. 181:4010.PubMed
  3. Niki T, et al. 2009. J. Biol. Chem. 284:32344. PubMed
  4. Shibui A, et al. 2011. Exp Parasitol. 129:318. PubMed
  5. Scatizzi JC, et al. 2012. J. Immunol. 188:3307. PubMed
  6. Yamakawa N, et al. 2012. Int Immunol. 25:45. PubMed
  7. Shibata T, et al. 2012. Int Immunol. 24:613. PubMed
  8. Baccala R, et al. 2012. J. Immunol. 189:5976. PubMed
  9. Grevers LC, et al. 2013. Ann Reheum Dis. 72:278. PubMed
  10. Woo SJ, et al. 2013. J Leukoc Biol. 93:363. PubMed
  11. Ashbaugh JJ, et al. 2013. J. Immunol. 190:4525. PubMed
  12. Reading JL, 2013. J. immunol. 190:4542. Pubmed.
  13. Kanno A, et al. 2013. Int Immunol. 25:413. PubMed
  14. Gunaydin G, et al. 2014. Vaccine. 32:470. PubMed
  15. Lyngaa R, et al. 2014. Clin Cancer Res. 20:1768. PubMed
  16. Datta S, et al. 2014. J Leukoc Biol. 95:853. PubMed
  17. He X, et al. 2014. J Immunol. 193:1314. PubMed
  18. Wang W, et al. 2014. PNAS. 111:14466. PubMed
  19. Murakami Y, et al. 2014. J Immunol. 193:5208. PubMed
  20. Lucas A, et al. 2015. PLoS One. 10:117160. PubMed
  21. Kim Yu, et al. 2015. PLoS One. 10:120294. PubMed
  22. Hua X, et al. 2015. PloS One. 10:128039. PubMed
Product Citations
  1. Tas JMJ, et al. 2022. Immunity. 55:1856. PubMed
  2. Melzi E, et al. 2022. Immunity. 55:2168. PubMed
  3. Vyasamneni R, et al. 2023. Cell Rep Methods. 3:100388. PubMed
  4. Ke F, et al. 2023. Elife. 12:. PubMed
  5. Li D, et al. 2023. Int J Oncol. 62:. PubMed
  6. Silva RP, et al. 2023. Elife. 12:. PubMed
  7. Nozuma S, et al. 2023. JCI Insight. 8:. PubMed
  8. García-Vega M, et al. 2023. iScience. 26:106562. PubMed
  9. Liu Y, et al. 2023. Nat Commun. 14:2179. PubMed
  10. Fathi M, et al. 2023. iScience. 26:106482. PubMed
  11. Xiao C, et al. 2023. Nat Aging. 3:418. PubMed
  12. Lv X, et al. 2023. Acta Pharm Sin B. 13:1631. PubMed
  13. Li X, et al. 2023. Nat Commun. 14:2929. PubMed
  14. Tundidor I, et al. 2023. Nat Commun. 14:3130. PubMed
  15. Chen K, et al. 2023. Gut Pathog. 15:28. PubMed
  16. Golubovskaya V, et al. 2023. Cancers (Basel). 15:. PubMed
  17. Martínez-Blanco Á, et al. 2021. Front Immunol. 12:713697. PubMed
  18. Wu Y, et al. 2021. Immunity. 54:2595. PubMed
  19. Goel RR, et al. 2022. Cell. 185:1875. PubMed
  20. Campisi L, et al. 2022. Nature. 606:945. PubMed
  21. Grégoire C, et al. 2022. Immunity. 55:1216. PubMed
  22. Wu Y, et al. 2022. Sci Adv. 8:eabm7833. PubMed
  23. Cao Y, et al. 2023. Nature. 614:521. PubMed
  24. Weskamm LM, et al. 2022. STAR Protoc. 3:101902. PubMed
  25. Mekkaoui L, et al. 2023. Mol Ther Methods Clin Dev. 28:116. PubMed
  26. Lombard-Vadnais F, et al. 2023. iScience. 26:105852. PubMed
  27. Hernandez SPA, et al. 2023. Front Immunol. 13:1035344. PubMed
  28. Pušnik J, et al. 2023. Nat Commun. 14:572. PubMed
  29. Knyphausen P, et al. 2023. Nat Commun. 14:768. PubMed
  30. Yeh CH, et al. 2022. Immunity. 55:272. PubMed
  31. Feng J, et al. 2022. Immunity. 55:405. PubMed
  32. Eger C, et al. 2016. PLoS One. 11: 0150479. PubMed
  33. Yang J, et al. 2016. Sci Rep. 6:38238. PubMed
  34. Chen T, et al. 2016. J Exp Med. 13(13):3025-3039. PubMed
  35. Zhang Y, et al. 2017. Journal of Immunological Methods. 10.1016/j.taap.2017.05.020. PubMed
  36. Wang H, et al. 2020. Mol Oncol. 14:991. PubMed
  37. Lv X, et al. 2022. Acta Pharm Sin B. 12:735. PubMed
  38. Muliaditan T, et al. 2021. Cell Rep Med. 2:100457. PubMed
  39. Tian L, et al. 2021. Int J Mol Sci. 22: . PubMed
  40. Trendel N, et al. 2021. Sci Signal. 14:eaay9363. PubMed
  41. Gatineau J, et al. 2022. Front Immunol. 13:982839. PubMed
  42. Yamakawa N, et al. 2012. Int Immunol. 25:45. PubMed
  43. Grevers L, et al. 2013. Ann Rheum Dis. 72:278. PubMed
  44. Datta S, et al. 2014. J Leukoc Biol. 95:853. PubMed
  45. Larsen SB, et al. 2021. Cell Stem Cell. 28:1758. PubMed
  46. Delás MJ, et al. 2019. Cell Rep. 27:719. PubMed
  47. Viborg N, et al. 2019. Oncoimmunology. 8:e1663107. PubMed
  48. Hernandez-Franco JF, et al. 2022. Front Immunol. 13:990900. PubMed
  49. Liang Q, et al. 2022. iScience. 25:104043. PubMed
  50. Xiao C, et al. 2022. iScience. 25:103934. PubMed
  51. Imbrechts M, et al. 2022. iScience. 25:104705. PubMed
  52. Biswas S, et al. 2021. Nature. 591:464. PubMed
  53. Wellner A, et al. 2021. Nat Chem Biol. 17:1057. PubMed
  54. Gniffke EP, et al. 2020. medRxiv. . PubMed
  55. Ruiz–Camp J, et al. 2019. EMBO Mol Med. 11:3. PubMed
  56. Nie X, et al. 2017. Cellular & Molecular Immunology. 10.1038/cmi.2017.17. PubMed
  57. Hu Y, et al. 2022. Nat Commun. 13:5313. PubMed
  58. Ashbaugh J, et al. 2013. J Immunol. 190:4525. PubMed
  59. Kim Y, et al. 2015. PLoS One. 10:120294. PubMed
  60. Yamamoto K, et al. 2021. Cell Reports. 36(8):109576. PubMed
  61. Hayatsu N et al. 2017. Immunity. 47(2):268-283 . PubMed
  62. Fukushima T, et al. 2019. Cell Rep. 29:4144. PubMed
  63. Cao Y, et al. 2022. Nature. :. PubMed
  64. He X, et al. 2021. Emerg Microbes Infect. 10:1555. PubMed
  65. Im S, et al. 2016. Nature. 537:417-421. PubMed
  66. Nishimoto K, et al. 2008. J Immunol. 181:4010. PubMed
  67. Schanda N, et al. 2021. Cells. 10:. PubMed
  68. Tsukamoto H, et al. 2013. Biochem Biophys Res Commun. 440:31. PubMed
  69. Phiwpan K, et al. 2015. PLoS One. 10:128198. PubMed
  70. Weiß S, et al. 2020. J Infect Dis. 222:1629. PubMed
  71. Pfenninger P, et al. 2022. Front Immunol. 13:777113. PubMed
  72. Kristensen NP, et al. 2022. J Clin Invest. 132:. PubMed
  73. Qiu C, et al. 2022. Front Immunol. 12:764949. PubMed
  74. Cao Y, et al. 2022. Nature. 602:657. PubMed
  75. Rogers BM, et al. 2021. J Exp Med. 218:. PubMed
  76. Köchl R, et al. 2020. Elife. 9:00. PubMed
  77. Lucas A, et al. 2015. PLoS One. 10:117160. PubMed
  78. Niki T, et al. 2009. J Biol Chem. 284:32344. PubMed
  79. Ping Y, et al. 2020. Front Cell Dev Biol. 0.890972222. PubMed
  80. Lv Z, et al. 2020. Oncoimmunology. 9:1747688. PubMed
  81. Morimoto A, et al. 2021. Nat Commun. 12:2136. PubMed
  82. Mei H, et al. 2021. J Hematol Oncol. 14:161. PubMed
  83. Repáraz D, et al. 2022. J Immunother Cancer. 10:. PubMed
  84. Reading J, et al. 2013. J Immunol. 190:4542. PubMed
  85. Weiß S, et al. 2020. medRxiv. . PubMed
  86. Dietmar Herndler‐Brandstetter et al. 2018. Immunity. 48(4):716-729 . PubMed
  87. Kim C, et al. 2019. Cell Rep. 29:2202. PubMed
  88. Hansen UK, et al. 2020. Front Immunol. 11:373. PubMed
  89. Hebbar N, et al. 2022. Nat Commun. 13:587. PubMed
  90. Tschismarov R, et al. 2021. JCI Insight. 6:. PubMed
  91. Richardson LS, et al. 2020. Lab Chip. 3.948611111. PubMed
  92. McWilliam H, et al. 2016. Nat Immunol. 17: 531-537. PubMed
  93. Zhang S, et al. 2016. Sci Transl Med. 8: 341ra77. PubMed
  94. Van Gool F, et al. 2019. Immunity. 50:362. PubMed
  95. Kacherovsky N, et al. 2019. Nat Biomed Eng. 0.66875. PubMed
  96. Parente-Pereira AC, et al. 2022. STAR Protoc. 3:101319. PubMed
  97. Baltierra-Uribe SL, et al. 2021. Eur J Immunol. 51:2641. PubMed
  98. Schoutrop E, et al. 2022. Oncoimmunology. 11:2093426. PubMed
  99. Jiang Y, et al. 2021. Cell Death Differ. 28:3009. PubMed
  100. Mainini F, et al. 2015. PLoS One. 10: 0145403. PubMed
  101. Woo S, et al. 2013. J Leukoc Biol. 93:363. PubMed
  102. Baccala R, et al. 2012. J Immunol. 189:5976. PubMed
  103. Delacher M, et al. 2020. Immunity. 52:295. PubMed
  104. Tsukamoto H, et al. 2017. FEBS Lett. 10.1002/1873-3468.12768. PubMed
  105. Guo C, et al. 2021. Cell Rep Med. 2:100448. PubMed
  106. Chen YL, et al. 2021. J Biol Chem. :101420. PubMed
  107. Zhong MC, et al. 2021. J Exp Med. 218:. PubMed
  108. Mudd PA, et al. 2022. Cell. 185:603. PubMed
  109. Günaydın G, et al. 2014. Vaccine. 32:470. PubMed
  110. Matt P, et al. 2015. PLoS One. 10: 0137474. PubMed
  111. Davis Z, et al. 2016. PLoS Pathog. 12: 1005421. PubMed
  112. Roewe J, et al. 2020. Nat Commun. 3.260416667. PubMed
  113. Tian B, et al. 2017. Front Immunol. 10.3389/fimmu.2017.00956. PubMed
  114. Schoofs T et al. 2019. Immunity. 50(6):1513-1529 . PubMed
  115. Carestia A, et al. 2019. Cell Rep. 28:896. PubMed
  116. Scatizzi J, et al. 2012. J Immunol. 188:3307. PubMed
  117. Matsuda T, et al. 2022. iScience. 25:105324. PubMed
  118. Kim SP, et al. 2022. Cancer Immunol Res. :OF1. PubMed
  119. Cheloha RW, et al. 2021. RSC chem biol. 2:1692. PubMed
  120. Okamoto Y, et al. 2021. J Cell Sci. 134:. PubMed
  121. Gniffke EP, et al. 2020. J Infect Dis. 222:1965. PubMed
  122. Morikawa M, et al. 2016. PLoS One. 11:e0163607. PubMed
  123. Leung EYL, et al. 2020. Mol Ther Oncolytics. 16:289. PubMed
  124. Nowak W, et al. 2020. EBioMedicine. 50:290-305.. PubMed
  125. Hoffmann J, et al. 2021. Nat Commun. 12:3964. PubMed
  126. Wang W, et al. 2014. Proc Natl Acad Sci U S A. 111:14466. PubMed
  127. Miyauchi K, et al. 2016. Nat Immunol. 17:1447-1458. PubMed
  128. Andersen TK, et al. 2019. NPJ Vaccines. 4:9. PubMed
  129. Lu X, et al. 2019. Cell Rep. 28:472. PubMed
  130. Leary N, et al. 2022. J Extracell Vesicles. 11:e12197. PubMed
  131. Dan JM, et al. 2021. Science. :371. PubMed
  132. He X, et al. 2014. J Immunol. 193:1314. PubMed
  133. Kanno A, et al. 2013. Int Immunol. 25:413. PubMed
  134. Walker MR, et al. 2022. Sci Adv. 8:eabj9513. PubMed
  135. Yang Zhou J, et al. 2022. Front Immunol. 13:898473. PubMed
  136. Deng J, et al. 2021. J Leukoc Biol. 110:1171. PubMed
  137. Murakami Y, et al. 2014. J Immunol. 193:5208. PubMed
  138. Mchedlidze T, et al. 2016. Mucosal Immunol. 10.1038/mi.2016.20. PubMed
  139. Wang EY, et al. 2022. Cell Rep Methods. 2:. PubMed
  140. Kurashima Y, et al. 2021. Nat Commun. 12:1067. PubMed
  141. Wells DK, et al. 2020. Cell. 183:818. PubMed
  142. Schürch CM, et al. 2020. Cell. 182:1341. PubMed
  143. DanDan Huang, Lang Bao 2016. J Microbiol Immunol Infect. 49:859-865. PubMed
  144. Chappaz S, et al. 2010. J Immunol. 185:3514. PubMed
  145. Altman JB, et al. 2018. Health Sci Rep. 1:e74. PubMed
  146. Hirunwidchayarat W, et al. 2017. Biochem Biophys Res Commun. 10.1016/j.bbrc.2017.07.012. PubMed
  147. Xiao C, et al. 2021. STAR Protoc. 2:100789. PubMed
  148. Rodrigues KA, et al. 2021. Sci Adv. 7:eabj6538. PubMed
  149. Szeto C, et al. 2022. Nat Commun. 13:4951. PubMed
  150. Lyngaa R, et al. 2014. Clin Cancer Res. 20:1768. PubMed
  151. Tripathi S, et al. 2016. Proc Natl Acad Sci U S A. 113: 1555 - 1564. PubMed
  152. Ando Y, Oku T, Tsuji T 2016. PLoS One. 11: 0162208. PubMed
  153. Zheng Q, et al. 2017. Mol Oncol. 10.1002/1878-0261.12056. PubMed
  154. Pedersen NW, et al. 2019. Nat Commun. 10:837. PubMed
  155. Yang C, et al. 2019. Nat Commun. 10:3931. PubMed
  156. Wirasinha RC, et al. 2021. J Exp Med. 218: . PubMed
  157. Holm JS, et al. 2022. Nat Commun. 13:1935. PubMed
  158. Du Z, et al. 2020. J Allergy Clin Immunol. . PubMed
  159. Yoshikawa S, et al. 2016. Sci Rep. 6:18738. PubMed
  160. Shibui A, et al. 2011. Exp Parasitol. 129:318. PubMed
  161. Lautz JD, et al. 2019. Sci Rep. 9:10890. PubMed
  162. Kenney M, et al. 2017. Journal of Immunological Methods. 10.1016/j.jim.2017.07.001. PubMed

Related FAQs

What type of PE do you use in your conjugates?
We use R-PE in our conjugates.
Go To Top Version: 6    Revision Date: 06/17/2019

For Research Use Only. Not for diagnostic or therapeutic use.

 

This product is supplied subject to the terms and conditions, including the limited license, located at www.biolegend.com/terms) ("Terms") and may be used only as provided in the Terms. Without limiting the foregoing, BioLegend products may not be used for any Commercial Purpose as defined in the Terms, resold in any form, used in manufacturing, or reverse engineered, sequenced, or otherwise studied or used to learn its design or composition without express written approval of BioLegend. Regardless of the information given in this document, user is solely responsible for determining any license requirements necessary for user’s intended use and assumes all risk and liability arising from use of the product. BioLegend is not responsible for patent infringement or any other risks or liabilities whatsoever resulting from the use of its products.

 

BioLegend, the BioLegend logo, and all other trademarks are property of BioLegend, Inc. or their respective owners, and all rights are reserved.

 

8999 BioLegend Way, San Diego, CA 92121 www.biolegend.com
Toll-Free Phone: 1-877-Bio-Legend (246-5343) Phone: (858) 768-5800 Fax: (877) 455-9587

ProductsHere
Login / Register
Remember me
Forgot your password? Reset password?
Create an Account